个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges.

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Shao YuTing[1] * ; Ma Li[1] ; Zhang TieHui[2] ; Xu TianRui[1] ; Ye YuanChao[3,4,*1,*2,*3] ; Liu Ying[1,*1,*2,*3] ;
机构： [1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, China [2]The First People's Hospital of Heishan County, Jinzhou city, Liaoning, Jinzhou 121400, China [3]Department of Internal Medicine, Gastroenterology and Hepatology, University of Iowa, Iowa City, IA 52242, USA [4]Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA 52242, USA
出处：
DOI： 10.2174/1568026619666190828162217
ISSN：

摘要：
KRAS is a member of the murine sarcoma virus oncogene-RAS gene family. It plays an important role in the prevention, diagnosis and treatment of tumors during tumor cell growth and angiogenesis. KRAS is the most commonly mutated oncogene in human cancers, such as pancreatic cancers, colon cancers, and lung cancers. Detection of KRAS gene mutation is an important indicator for tracking the status of oncogenes, highlighting the developmental prognosis of various cancers, and the efficacy of radiotherapy and chemotherapy. However, the efficacy of different patients in clinical treatment is not the same. Since RNA interference (RNAi) technologies can specifically eliminate the expression of specific genes, these technologies have been widely used in the field of gene therapy for exploring gene function, infectious diseases and malignant tumors. RNAi refers to the phenomenon of highly specific degradation of homologous mRNA induced by double-stranded RNA (dsRNA), which is highly conserved during evolution. There are three classical RNAi technologies, including siRNA, shRNA and CRISPR-Cas9 system, and a novel synthetic lethal interaction that selectively targets KRAS mutant cancers. Therefore, the implementation of individualized targeted drug therapy has become the best choice for doctors and patients. Thus, this review focuses on the current status, future perspective and associated challenges in silencing of KRAS with RNAi technology. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

基金：
This work was funded by NSFC funding (81560455, 81473342, 81460417, 81460253).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 3 区 医学
小类 | 3 区 药物化学
最新[2023]版：
大类 | 4 区 医学
小类 | 4 区 药物化学
第一作者：
第一作者机构： [1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, China
通讯作者：
通讯机构： [1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, China [3]Department of Internal Medicine, Gastroenterology and Hepatology, University of Iowa, Iowa City, IA 52242, USA [4]Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA 52242, USA [*1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, China [*2]Department of Internal Medicine, Gastroenterology and Hepatology, University of Iowa, Iowa City, IA 52242, USA [*3]Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA 52242, USA
推荐引用方式(GB/T 7714)：
Shao YuTing,Ma Li,Zhang TieHui,et al.The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges.[J].Current topics in medicinal chemistry.2019,19(23):2143-2157.doi:10.2174/1568026619666190828162217.
APA：
Shao YuTing,Ma Li,Zhang TieHui,Xu TianRui,Ye YuanChao&Liu Ying.(2019).The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges..Current topics in medicinal chemistry,19,(23)
MLA：
Shao YuTing,et al."The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges.".Current topics in medicinal chemistry 19..23(2019):2143-2157

资源点击量：82490 今日访问量：0 总访问量：681 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西山区金碧路157号